Home page Home page

Riprazo HCT
aliskiren, hydrochlorothiazide

PACKAGE LEAFLET: INFORMATION FOR THE USER


Riprazo HCT 150 mg/12.5 mg film-coated tablets Riprazo HCT 150 mg/25 mg film-coated tablets Riprazo HCT 300 mg/12.5 mg film-coated tablets Riprazo HCT 300 mg/25 mg film-coated tablets Aliskiren/hydrochlorothiazide


Read all of this leaflet carefully before you start taking this medicine.


Your doctor may need to change your dose and/or take other precautions if you are taking one of the following medicines:


Taking Riprazo HCT with food and drink

You should take Riprazo HCT with a light meal once a day, preferably at the same time each day. You should not take Riprazo HCT together with grapefruit juice.


Pregnancy

You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Riprazo HCT before you become pregnant or as soon as you know you are

pregnant and will advise you to take another medicine instead of Riprazo HCT. Riprazo HCT is not

recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.

Breast-feeding

Tell your doctor if you are breast-feeding or about to start breast-feeding. Riprazo HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for

you if you wish to breast-feed.


Ask your doctor or pharmacist for advice before taking any medicine.


Driving and using machines

As with many other medicines used to treat high blood pressure, this medicine may make you feel dizzy. If you experience this symptom, do not drive or use tools or machines.


Important information about some of the ingredients of Riprazo HCT

Riprazo HCT contains lactose (milk sugar). If you have been told by your doctor that you have an

intolerance to some sugars, contact your doctor before taking this medicine.


Riprazo HCT contains wheat starch. It is suitable for people with coeliac disease. Patients with wheat allergy (different from coeliac disease) should not take this medicine.


  1. HOW TO TAKE RIPRAZO HCT


    Always take Riprazo HCT exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.


    Medicinal product no longer authorised

    The usual dose of Riprazo HCT is one tablet a day. Swallow the tablet whole with some water. You should take Riprazo HCT with a light meal once a day, preferably at the same time each day. You should not take Riprazo HCT together with grapefruit juice. During your treatment, your doctor may adjust your dose depending on your blood pressure response.


    Riprazo HCT may have been prescribed to you because your previous treatment did not lower your blood pressure enough. If this is the case, your doctor will tell you how to switch from that treatment to Riprazo HCT.


    If you take more Riprazo HCT than you should

    If you have accidentally taken too many Riprazo HCT tablets, talk to a doctor immediately. You may

    require medical attention.


    If you forget to take Riprazo HCT

    If you forget to take a dose of this medicine, take it as soon as you remember and then take the next

    dose at its usual time. If it is almost time for your next dose you should simply take the next tablet at the usual time. Do not take a double dose (two tablets at once) to make up for a forgotten tablet.


    Do not stop taking this medicine, even if you are feeling well (unless your doctor tells you to do so). People who have high blood pressure often do not notice any signs of the problem. Many may feel quite normal. It is very important that you take this medicine exactly as your doctor tells you to get the best results and reduce the risk of side effects. Keep your appointments with the doctor even if you are feeling well.

    If you have further questions on the use of this product, ask your doctor or pharmacist.

  2. POSSIBLE SIDE EFFECTS


    Like all medicines, Riprazo HCT can cause side effects, although not everybody gets them.


    If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. You may need to stop Riprazo HCT.


    Side effects reported in clinical studies for patients treated with Riprazo HCT were: Common (affecting less than 1 in 10 patients):

    • Diarrhoea


      As for any combination of two active substances, side effects associated with each individual component cannot be excluded.

      Aliskiren:

      Common (affecting less than 1 in 10 patients):

    • Diarrhoea

    • Joint pain (arthralgia)

    • High level of potassium in the blood

    • Dizziness


      Uncommon (affecting less than 1 in 100 patients):

    • Skin rash (this may also be a sign of allergic reactions or angioedema – see “Rare” side effects below)

    • Kidney problems including acute renal failure (severely decreased urine output)

    • Swelling of hands, ankles or feet (peripheral oedema)

    • Severe skin reactions (toxic epidermal necrolysis and/or oral mucosal reactions - red skin, blistering of the lips, eyes or mouth, skin peeling, fever)

      Medicinal product no longer authorised

    • Low blood pressure


      Rare (affecting less than 1 in 1,000 patients):

    • Allergic reactions (hypersensitivity) and angioedema (the symptoms of which can include difficulties in breathing or swallowing, rash, itching, hives or swelling of the face, hands and feet, eyes, lips and/or tongue, dizziness)

    • Increased level of creatinine in the blood.


      Hydrochlorothiazide:

      Very common (affecting more than 1 in 10 patients):

    • Low level of potassium in the blood

    • Increase of lipids in the blood


      Common (affecting less than 1 in 10 patients):

    • High level of uric acid in the blood

    • Low level of magnesium in the blood

    • Low level of sodium in the blood

    • Dizziness, fainting on standing up

    • Reduced appetite

    • Nausea and vomiting

    • Itchy rash and other types of rash

    • Inability to achieve or maintain erection

      Rare (affecting less than 1 in 1,000 patients):

    • Low level of blood platelets (sometimes with bleeding or bruising underneath the skin)

    • High level of calcium in the blood

    • High level of sugar in the blood

    • Worsening of the diabetic metabolic state

    • Sad mood (depression)

    • Sleep disturbances

    • Dizziness

    • Headache

    • Tingling or numbness

    • Vision disorder

    • Irregular heart beat

    • Abdominal discomfort

    • Constipation

    • Diarrhoea

    • Liver disorders which can occur together with yellow skin and eyes

    • Increased sensitivity of skin to the sun

    • Sugar in the urine


      Very rare (affecting less than 1 in 10,000 patients):

    • Fever, sore throat or mouth ulcers, more frequent infections (lack or low level of white blood cells)

    • Pale skin, tiredness, breathlessness, dark-coloured urine (haemolytic anaemia)

    • Rash, itching, hives, difficulty breathing or swallowing, dizziness (hypersensitivity reactions)

    • Confusion, tiredness, muscle twitching and spasm, rapid breathing (hypochloraemic alkalosis)

      Medicinal product no longer authorised

    • Difficulty breathing with fever, coughing, wheezing, breathlessness (respiratory distress including pneumonitis and pulmonary oedema)

    • Severe upper stomach pain (pancreatitis)

    • Facial rash, joint pain, muscle disorder, fever (lupus erythematosus)

    • Inflammation of blood vessels with symptoms such as rash, purplish-red spots, fever (vasculitis)

    • Severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (toxic epidermal necrolysis)


      Not known (frequency cannot be estimated from the available data):

    • Weakness

    • Bruising and frequent infections (aplastic anaemia)

    • Decrease in vision or pain in your eyes due to high pressure (possible signs of acute-angle closure glaucoma)

    • Severe skin disease that causes rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (erythema multiforme)

    • Muscle spasm

    • Severely decreased urine output (possible signs of renal disorder or renal failure), weakness (asthenia)

    • Fever


  3. HOW TO STORE RIPRAZO HCT


    Keep out of the reach and sight of children.

    Do not use Riprazo HCT after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

    Do not store above 30°C.

    Store in the original package in order to protect from moisture.

  4. FURTHER INFORMATION


What Riprazo HCT contains

hemifumarate) and 25 mg hydrocholorothiazide. The other ingredients are: cellulose microcrystalline, crospovidone, lactose monohydrate, wheat starch, povidone, magnesium stearate, silica colloidal anhydrous, talc, hypromellose, macrogol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172).


What Riprazo HCT looks like and contents of the pack

Riprazo HCT 150 mg/12.5 mg film-coated tablets are white, oval film-coated tablets imprinted with

“LCI” on one side and “NVR” on the other.

Medicinal product no longer authorised

Riprazo HCT 150 mg/25 mg film-coated tablets are pale yellow, oval film-coated tablets imprinted with “CLL” on one side and “NVR” on the other.

Riprazo HCT 300 mg/12.5 mg film-coated tablets are violet white, oval film-coated tablets imprinted with “CVI” on one side and “NVR” on the other.

Riprazo HCT 300 mg/25 mg film-coated tablets are light yellow, oval film-coated tablets imprinted with “CVV” on one side and “NVR” on the other.


Riprazo HCT is available in packs containing 7, 14, 28, 30, 50, 56, 90,or 98 tablets. Packs containing 90 (3x30), 98 (2x49) or 280 (20x14) tablets are multi-packs.


Not all pack sizes or strengths may be available in your country.


Marketing Authorisation Holder Novartis Europharm Limited Wimblehurst Road

Horsham

West Sussex, RH12 5AB United Kingdom


Manufacturer

Novartis Farma S.p.A.

Via Provinciale Schito 131

I-80058 Torre Annunziata/NA Italy


For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:


België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11

Luxembourg/Luxemburg Novartis Pharma GmbH Tél/Tel: +49 911 273 0

България

Novartis Pharma Services Inc.

Тел.: +359 2 489 98 28

Magyarország

Novartis Hungária Kft. Pharma

Tel.: +36 1 457 65 00


Česká republika

Novartis s.r.o.

Tel: +420 225 775 111

Malta

Novartis Pharma Services Inc.

Tel: +356 2298 3217


Danmark

Novartis Healthcare A/S Tlf: +45 39 16 84 00

Nederland

Novartis Pharma B.V. Tel: +31 26 37 82 111


Deutschland

Novartis Pharma GmbH

Tel: +49 911 273 0

Norge

Novartis Norge AS

Tlf: +47 23 05 20 00


Eesti

Novartis Pharma Services Inc. Tel: +372 66 30 810

Österreich

Novartis Pharma GmbH Tel: +43 1 86 6570


Ελλάδα

Novartis (Hellas) A.E.B.E.

Τηλ: +30 210 281 17 12

Polska

Novartis Poland Sp. z o.o.

Tel.: +48 22 375 4888


España

Laboratorios Dr. Esteve, S.A.

Medicinal product no longer authorised

Tel: +34 93 446 60 00

Portugal

Novartis Farma - Produtos Farmacêuticos, S.A.

Tel: +351 21 000 8600


France

Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00

România

Novartis Pharma Services Romania SRL Tel: +40 21 31299 01


Ireland

Novartis Ireland Limited

Tel: +353 1 260 12 55

Slovenija

Novartis Pharma Services Inc.

Tel: +386 1 300 75 50


Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439


Italia

Novartis Farma S.p.A. Tel: +39 02 96 54 1

Suomi/Finland

Novartis Finland Oy

Puh/Tel: +358 (0)10 6133 200


Κύπρος

Novartis Pharma Services Inc.

Τηλ: +357 22 690 690

Sverige

Novartis Sverige AB

Tel: +46 8 732 32 00


Latvija

Novartis Pharma Services Inc. Tel: +371 67 887 070

United Kingdom

Novartis Pharmaceuticals UK Ltd. Tel: +44 1276 698370


Lietuva

Novartis Pharma Services Inc. Tel: +370 5 269 16 50

This leaflet was last approved in


Medicinal product no longer authorised

.eu